doi: 10.1161/CIRCULATIONAHA.107.702795
(Circulation. 2007;116:434-448.)
© 2007 American Heart Association, Inc.
Basic Science for Clinicians |
Metabolic Mechanisms in Heart Failure
From the Department of Cardiovascular Medicine (H.A.), University of Oxford, Oxford, and the Department of Cardiovascular Medicine (M.P.F.), University of Birmingham, Edgbaston, UK; and the Hatter Institute for Cardiovascular Research (L.H.O.), Cape Heart Centre and Department of Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa.
Correspondence to Dr Houman Ashrafian, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. E-mail houman.ashrafian{at}cardiov.ox.ac.uk
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the residual disability and death rate remains unacceptably high. Though abnormalities of myocardial metabolism are associated with heart failure, recent data suggest that heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation. A detrimental self-perpetuating cycle (heart failure 
altered metabolism heart failure) that promotes the progression of heart failure may thus be postulated. Accordingly, we review the cellular mechanisms and pathophysiology of altered metabolism and insulin resistance in heart failure. It is hypothesized that the ensuing detrimental myocardial energetic perturbations result from neurohumoral activation, increased adverse free fatty acid metabolism, decreased protective glucose metabolism, and in some cases insulin resistance. The result is depletion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical work. On the basis of the mechanisms outlined, appropriate therapies to mitigate aberrant metabolism include intense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet. We also discuss more novel mechanistic-based therapies to ameliorate metabolism and insulin resistance in heart failure. For example, metabolic modulators may optimize myocardial substrate utilization to improve cardiac function and exercise performance beyond standard care. The ultimate success of metabolic-based therapy will be manifest by its capacity further to lessen the residual mortality in heart failure.
Key Words: fatty acids • glucose • heart failure • insulin resistance
This article has been cited by other articles:
 |
|
 |
|
  T. H. Marwick and M. Schwaiger The Future of Cardiovascular Imaging in the Diagnosis and Management of Heart Failure, Part 1: Tasks and Tools Circ Cardiovasc Imaging, July 1, 2008; 1(1): 58 - 69. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tominaga, H. Katoh, K. Odagiri, Y. Takeuchi, H. Kawashima, M. Saotome, T. Urushida, H. Satoh, and H. Hayashi Different effects of palmitoyl-L-carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H105 - H112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doenst, H. Bugger, M. Schwarzer, G. Faerber, M. A. Borger, and F. W. Mohr Three good reasons for heart surgeons to understand cardiac metabolism Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 862 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Opie Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia Circulation, April 29, 2008; 117(17): 2172 - 2177. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, Y. Wei, and J. R. Sowers Role of Mitochondrial Dysfunction in Insulin Resistance Circ. Res., February 29, 2008; 102(4): 401 - 414. [Abstract] [Full Text] [PDF]
|
|